Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Soleno Therapeutics ( (SLNO) ) just unveiled an announcement.
On June 5, 2025, Soleno Therapeutics held its Annual Meeting of Stockholders, where approximately 94.7% of the outstanding shares were represented. The stockholders elected two Class II directors and ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (SLNO) stock is a Buy with a $93.00 price target. To see the full list of analyst forecasts on Soleno Therapeutics stock, see the SLNO Stock Forecast page.
Spark’s Take on SLNO Stock
According to Spark, TipRanks’ AI Analyst, SLNO is a Underperform.
Soleno Therapeutics shows high risk due to its lack of revenue and reliance on external financing. However, it maintains a solid equity base and is experiencing positive technical momentum, suggesting speculative interest. The valuation is typical for an early-stage biotech, with potential upside reliant on successful R&D outcomes.
To see Spark’s full report on SLNO stock, click here.
More about Soleno Therapeutics
Soleno Therapeutics, Inc. operates in the biotechnology industry, focusing on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Average Trading Volume: 1,335,437
Technical Sentiment Signal: Buy
Current Market Cap: $3.88B
Find detailed analytics on SLNO stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue